araag2/HINT huggingface dataset:
Clinical trial NCT00088504 (phase 2, status: completed)
Conditions: hepatitis c, hepatitis
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: merimepodib, peg-interferon-alpha 2a (pegasys®), ribavirin (copegus®)
SMILES: COC1=C(C=CC(NC(=O)NC2=CC=CC(CNC(=O)O[C@H]3CCOC3)=C2)=C1)C1=CN=CO1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

        The following is a summary of the inclusion and exclusion criteria for the Merimepodib
        Triple Combination (METRO) trial. There are also additional criteria, which will be
        reviewed with you by the staff at the clinical study site, to make sure you are eligible
        for the study. Some of the criteria are dependent on the results of blood tests and other
        tests that will be done at the clinical site.

        If you are not sure whether you meet these criteria, please call the clinical study site
        nearest you, and they can help you figure out if you might be eligible for the study:

          -  You must have been diagnosed with Hepatitis C.

          -  You must have been treated with pegylated interferon (brand names are Pegasys® or
             Peg-Intron®) and ribavirin (brand names Rebetol® or Copegus®), for at least 12 weeks.
             However, you cannot have received more than one course of this combination therapy.

          -  You must have been a "non-responder" to this treatment, meaning that the virus levels
             in your blood were always detectable. If you responded to the treatment and then the
             virus became detectable again (called a "relapse"), you would not be eligible.

          -  You must not have used illegal drugs, or have a history of significant alcohol use,
             within the last year before you start the study.

        Pegasys® and Copegus® are not recommended for people with some illnesses. You should be in
        good health in general, with no illnesses that would prevent you from using Pegasys® and
        Copegus®. If you do not know whether you have any illness or conditions that would prevent
        you from using these medications, the study doctor or nurse will review your medical
        history with you to determine this.

        If you are a woman who can have children, you must be willing to use two effective methods
        of birth control during the study and for 6 months after the last dose of the medication.
        You will have monthly pregnancy tests during this time to make sure you do not become
        pregnant (This is recommended for anyone taking ribavirin, even when they are not in a
        clinical study.).

        If you are a male, your female partner must not be pregnant, and you both must be willing
        to use birth control during the time you are in the study, and for 6 months after the last
        dose of the medication (This is recommended for anyone taking ribavirin, even when they are
        not in a clinical study.).
Clinical trial NCT00476112 (phase 2/phase 3, status: completed)
Conditions: atrial flutter
ICD codes: I48.3, I48.4, I48.92
Drugs: vernakalant injection 20 mg/ml
SMILES: COC1=C(OC)C=C(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older.

          -  Have an atrial arrhythmia with dysrhythmic symptoms that has been sustained for
             greater than 3 hours and up to 45 days.

          -  Have adequate anticoagulant therapy.

        Exclusion Criteria:

          -  Have a QRS > 0.14 s unless patient has pacemaker or uncorrected QT > 0.440 seconds as
             measured on a 12-lead ECG.

          -  Be concurrently participating in another drug study or have received an
             investigational drug within 30 days prior to enrollment, or have previously received
             RSD1235.

          -  Have serious diseases/illnesses that could interfere with the conduct or validity of
             the study or compromise patient safety.

          -  Have received IV Class I or Class III antiarrhythmic drugs or IV amiodarone within 24
             hours prior to dosing.
Clinical trial NCT00253591 (phase 2/phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, vinorelbine tartrate
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed stage I-III non-small cell lung cancer

               -  Inoperable or patient refuses surgery

          -  Disease can be encompassed within the radical radiotherapy treatment volume

        PATIENT CHARACTERISTICS:

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count > 100,000/mm^3

        Hepatic

          -  Bilirubin < 1.5 times upper limit of normal

        Renal

          -  Glomerular filtration rate > 60 mL/min

        Cardiovascular

          -  No uncontrolled arterial hypertension

          -  No ischemic heart disease

        Pulmonary

          -  FEV_1 > 50% of predicted OR

          -  DLCO > 50% of predicted

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior or current malignancy that would preclude study treatment

          -  Medically stable

          -  No unstable diabetes

          -  No infection

          -  No hypercalcemia

        PRIOR CONCURRENT THERAPY:

        Chemotherapy

          -  No prior chemotherapy

        Radiotherapy

          -  See Disease Characteristics

          -  No prior radiotherapy
Clinical trial NCT01350817 (phase 2, status: completed)
Conditions: non small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib + docetaxel, docetaxel
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven NSCLC (

          -  Mutational status of EGFR : wild type or unknown

          -  Stage IV disease with cytologic or histologic documentation in patients with a single
             easily accessible metastasis or metastatic relapses in a non irradiated region from a
             primary tumor treated with surgery or radiotherapy (with cytologic or histologic
             documentation of relapse)

          -  Presence of at least one measurable target lesion (one dimension) in a non irradiated
             region (at least 10 mm on spiral computed tomography).

          -  Age ≥ 18 years

          -  Performance status 0,1,2 exception : age > 74 years only PS 0 or 1

          -  Normal hepatic function

          -  Normal renal function

          -  Normal calcemia

          -  Normal haematological function

          -  Life expectancy > 12 weeks.

          -  Women of child bearing potential must use effective contraception.

          -  Men might be surgically sterile or accept to use an effective contraceptive procedure
             during and until 6 months after the treatment.

          -  Written informed consent to participate in the study.

        Exclusion Criteria:

          -  PS > 2, exception : age > 74 years only PS ≥ 2

          -  Presence of another cancer

          -  Previous treatment with an anti egfr agent or docetaxel

          -  QT prolongation (>470 ms)

          -  Uncontrolled arterial hypertension.

          -  Concurrent radiotherapy, except for palliative bone irradiation.

          -  Stroke less than 6 months before study entry.

          -  Psychiatric or neurological disorders preventing the patient from understanding the
             nature of the trial

          -  Uncontrolled infection.

          -  Caval syndrome

          -  Other organic disorders preventing inclusion in the trial

          -  Malabsorption syndrome

          -  Allergy to erlotinib or one of its constituents

          -  Allergy to docetaxel or one of its constituents

          -  Pregnancy and breast-feeding

          -  Surgery less than two months before study entry
Clinical trial NCT00092001 (phase 2, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: sunitinib
SMILES: CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic Non-Small Cell Lung Cancer that cannot
             be cured with surgery, radiation, or combination thereof

          -  No more than 2 prior chemotherapy treatments including treatment with a platinum
             containing therapy

          -  Evidence of measurable disease by radiographic technique

          -  Male or Female, 18 years or older

          -  ECOG performance status of 0 or 1

          -  Resolution of all acute toxicities of prior therapies

          -  Adequate organ function

        Exclusion Criteria:

          -  Major surgery or radiation therapy within 4 weeks

          -  Severe hemorrhage within 4 weeks

          -  Previous treatment with anti-angiogenesis agents

          -  Diagnosis of second malignancy within last five 5 years

          -  History of or known brain metastases, spinal cord compression, or carcinomatous
             meningitis

          -  Known HIV

          -  Serious acute or chronic illness

          -  Current treatment on another clinical trial

          -  Pregnant or breastfeeding
Clinical trial NCT01551888 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium/formoterol 400/12μg, formoterol
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Current or former cigarette smokers with a cigarette smoking history of at least 10
             pack-years

          -  A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined
             by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable
             airway obstruction.

        Exclusion Criteria:

          -  Patients who have been hospitalized for an acute COPD exacerbation within three months
             prior to Screening

          -  Any respiratory tract infection (including the upper respiratory tract) or COPD
             exacerbation in the six weeks before Screening

          -  Patients with any clinically significant respiratory conditions other than COPD

          -  Clinical history that suggests that the patient has asthma as opposed to COPD

          -  Chronic use of oxygen therapy ≥ 15 hours/day

          -  Patients with clinically significant cardiovascular conditions

          -  Patients with a history of hypersensitivity reaction to inhaled anticholinergics,
             beta-2 agonists, sympathomimetic amines, or inhaled medications
Clinical trial NCT00141531 (phase 2, status: completed)
Conditions: bladder neoplasms
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: apaziquone
SMILES: CN1C(\C=C\CO)=C(CO)C2=C1C(=O)C=C(N1CC1)C2=O
Eligibility criteria:

        Inclusion Criteria:

        1. Patients with high risk superficial bladder cancer according to EAU criteria defined as:

          -  pT1 and/or Grade 2b-3, or multiple and highly recurrent

          -  histologically confirmed carcinoma in situ 2. All visible lesions must be completely
             removed by transurethral resection (TUR) at entry to the study 3. Normal bimanual
             examination under anesthesia (no palpable masses) 4. Absence of upper urinary tract
             tumor confirmed by intravenous pyelography (IVP) or CT scan or retrograde urogram
             within 6 months from the beginning of treatment 5. Patient with ZUBROD-ECOG-WHO
             performance status of 0-2 (see Appendix 2) 6. Over 18 years of age 7. Patients must be
             fully informed of the investigational nature of the study and signed written informed
             consent must be obtained prior to any study specific investigations.

        Exclusion Criteria:

          1. Patients having muscle-invasive disease (T2 or greater)

          2. Prior intravesical treatment (chemotherapy or immunotherapy) within the last 3 months

          3. Patients with existing urinary tract infection or recurrent severe bacterial cystitis

          4. Patients with urogenital tumors with histology other than transitional cell carcinoma
             (i.e., squamous cell or adenocarcinoma) or with transitional carcinoma involving the
             upper tract or the prostatic urethra

          5. Patients with history of other primary malignancy (other than squamous or basal cell
             skin cancers or cone biopsied Cis of the uterine cervix or prostate carcinoma treated
             curatively with normal PSA values at inclusion) in the last five years

          6. Patients with active, uncontrolled impairment of the renal, hepatobiliary,
             cardiovascular, gastrointestinal, urogenital, neurologic or hematopoietic systems
             which, in the opinion of the investigator, would predispose to the development of
             complications from the administration of intravesical therapy and or general
             anesthesia

          7. Patients who, in the opinion of the investigator, cannot tolerate intravesical
             administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the
             presence of concomitant serious illness (i.e. uncontrolled cardiac or respiratory
             disorders)

          8. Women who are pregnant or lactating. Individuals of reproductive potential may not
             participate unless agreeing to use an effective contraceptive method for themselves
             and/or their sexual partner
Clinical trial NCT00049335 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed metastatic or recurrent colorectal cancer
             not amenable to surgical resection

          -  Measurable disease

          -  No known brain metastases by MRI or CT scan

        PATIENT CHARACTERISTICS:

        Age

          -  70 and over OR

          -  18 to 59

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute granulocyte count at least 1,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

          -  SGOT (serum glutamate oxaloacetate transaminase) or SGPT (serum glutamate pyruvate
             transaminase) no greater than 2 times ULN

        Renal

          -  Creatinine no greater than 2 times ULN

          -  Creatinine clearance greater than 50 mL/min

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No known seizure disorder

          -  No other malignancy except adequately treated basal cell or squamous cell skin cancer,
             carcinoma in situ of the cervix, adequately treated stage I or II cancer currently in
             complete remission, or any other cancer for which the patient has been disease free
             for 5 years

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for advanced cancer

          -  Prior adjuvant chemotherapy allowed provided recurrence occurred more than 1 year
             after the last treatment

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  At least 4 weeks since prior sorivudine or brivudine

          -  No concurrent sorivudine or brivudine
Clinical trial NCT00447057 (phase 2, status: completed)
Conditions: histological or cytological diagnosis of locally advanced or metastatic nsclc of nonsquamous histology and not amenable to curative therapy.
ICD codes: R86.7, R87.7, R82.89, R84.7, R85.7, R89.7
Drugs: pemetrexed, erlotinib, pemetrexed, erlotinib
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is
             of nonsquamous histology and not amenable to curative therapy.

          -  Failure of previous treatment with one prior platinum-based chemotherapy regimen.

          -  Good performance status.

          -  Adequate bone marrow reserve, renal and hepatic functions.

        Exclusion Criteria:

          -  Serious concomitant systemic disease.

          -  Inability to take oral medication.

          -  Inability or unwillingness to take vitamin supplementation and corticosteroids.

          -  Pregnancy / Breast-feeding.

          -  Treatment with certain medicines that prevent blood from clotting.
Clinical trial NCT00052949 (phase 2, status: completed)
Conditions: recurrent small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: imatinib mesylate
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed small cell lung cancer (SCLC)

               -  No mixed histology

          -  Must have received only 1 prior treatment regimen (e.g., cyclophosphamide,
             doxorubicin, and vincristine alternating with etoposide and cisplatin allowed)

          -  c-Kit positive by immunohistochemistry (at least 1+)

          -  At least 1 unidimensionally measurable lesion

               -  Longest diameter at least 20 mm

          -  No uncontrolled CNS metastasis

               -  Treated CNS metastasis allowed

          -  Performance status - ECOG 0-2

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 9 g/dL

          -  Total bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  Direct bilirubin no greater than ULN

          -  Creatinine no greater than 1.5 times ULN

          -  No unstable angina pectoris

          -  No uncontrolled congestive heart failure within the past 3 months unless ejection
             fraction is greater than 40%

          -  No myocardial infarction within the past 3 months

          -  No uncontrolled infection

          -  No other malignancy within the past 3 years except skin cancer or localized prostate
             cancer

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 3 months
             after study participation

          -  See Disease Characteristics

          -  More than 3 weeks since prior chemotherapy

          -  More than 2 weeks since prior radiotherapy

          -  No concurrent radiotherapy(including palliative therapy for bone pain)

               -  Concurrent whole-brain radiotherapy for CNS progression allowed

          -  More than 3 weeks since prior major surgery

          -  No prior imatinib mesylate
Clinical trial NCT00402597 (phase 2, status: completed)
Conditions: acute coronary syndrome
ICD codes: I24.0
Drugs: rivaroxaban/placebo, placebo, rivaroxaban
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have symptoms suggestive of ACS that lasted at least 10 minutes at rest occurring
             within 7 days of randomization

          -  Have a diagnosis of ST-elevation myocardial infarction or non-ST elevation myocardial
             infarction/unstable angina (ie, chest pain or discomfort) (ST elevation is an abnormal
             finding from an ECG test) with at least 1 protocol-defined high risk feature

        Exclusion Criteria:

          -  Active bleeding or high risk of bleeding or intracranial hemorrhage (bleeding within
             the skull enclosing the brain)

          -  Need for continued anticoagulant therapy

          -  Significantly impaired renal (kidney) or hepatic (liver) function

          -  Severe concomitant diseases such as cardiogenic shock (heart damage that results in
             insufficient blood supply to other parts or organs of the body), refractory
             ventricular arrhythmias (irregular contractions of the heart unresponsive to
             treatment), or any severe condition that would limit life expectancy of the patient to
             less than 6 months